High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1098-1105

  Motzer, R J ^a   Mazumdar, M ^a   Bosl, G J ^a   Bajorin, D F ^a   Amsterdam, A ^a   Vlamis, V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; TUMOR MARKER; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM TUMOR; METASTASIS; MULTICENTER STUDY; NEPHROTOXICITY; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROPERITONEAL TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TESTIS TUMOR; TREATMENT OUTCOME;

EID: 0029928705     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1098     Document Type: Article

References (32)

1. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
2. Bosl GJ, Geller NL, Bajorin D, et al: A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 6:1231-1238, 1988
3. Einhorn LH, Weathers T, Loehrer P, et al: Second line chemotherapy with vinblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin, VP-16, and bleomycin (PVBB) in disseminated germ cell tumors (GCT): Long term followup. Proc Am Soc Clin Oncol 11:196, 1992 (abstr 599)
4. Motzer RJ, Bajorin DF, Vlamis V, et al: Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 19:8-12, 1992
5. Motzer RJ, Geller NL, Tan CC, et al: Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310, 1991
6. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
7. Nichols CR, Tricot G, Williams SD, et al: Dose intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
8. Motzer RJ, Gulati SC, Crown JP, et al: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: Early intervention is better tolerated. Cancer 69:550-556, 1992
9. Motzer RJ, Gulati SC, Tong WP, et al: Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53:3730-3735, 1993
10. Linkesch W, Greinix HT, Hocker P, et al: Longterm follow up of phase I/II trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 717)
11. Cox DR, Oakes D: Analysis of Survival Data. New York, NY, Chapman & Hall, 1990
12. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
13. SAS/STAT User's Guide (ed 4). Cary, NC, SAS Institute, 1990
14. Wood DP, Herr HW, Motzer RJ, et al: Surgical resection of solitary metastases after chemotherapy in patients with non-seminomatous germ cell tumors and elevated serum tumor markers. Cancer 70:2354-2357, 1992
15. Murphy BR, Breeden ES, Donohue JP, et al: Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11:324-329, 1993
16. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
17. Broun ER, Nichols CR, Tricot G, et al: High dose carboplatin/ VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 7:53-56, 1991
18. Lotz JP, Machover D, Malassagne B, et al: Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors. J Clin Oncol 9:1860-1870, 1991
19. Siegert W, Beyer J, Strohscheer I, et al: High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. J Clin Oncol 12:1223-1231, 1994
20. Rosti G, Albertazzi L, Salvioni R, et al: High dose chemotherapy with carboplatin. VP 16 +/- ifosfamide in germ cell tumors: The Italian experience. Bone Marrow Transplant 7:94, 1991 (suppl 2)
21. Margolin K, Doroshow J, Ahn C, et al: High-dose carboplatin, VP-16, and ifosfamide with autlogous bone marrow support in relapsed germ cell tumors. Proc Am Soc Clin Oncol 12:252, 1993 (abstr 794)
22. Elias A, Kantoff P, Ayashi L, et al: High-dose ifosfamide, carboplatin and etoposide (ICE) with autologous marrow support for germ cell carcinoma. Proc Am Soc Clin Oncol 12:252, 1993 (abstr 710)
23. Droz JP, Kramur A, Pico JL: Prediction of long term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non seminomatous germ cell tumors. Eur J Cancer 29A:818-821, 1993
24. Linkesch W, Krainer M, Wagner A: Phase I/II trial of ultra-high carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors. Bone Marrow Transplant 10:28-29, 1992 (suppl 2)
25. Beyer J, Schwella N, Zingsem J, et al: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335, 1995
26. Murphy BA, Motzer RJ, Mazumdar M, et al: Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage therapy. Cancer 73:2520-2526, 1994
27. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
28. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
29. Chou T-C, Motzer RJ, Tong Y, et al: Computerized quantification of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524, 1994
30. Motzer RJ, Chou TC, Schwartz L, et al: Paclitaxel in germ cell cancer. Semin Oncol 22:12-15, 1995 (suppl 6)
31. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986
32. Coldman AJ, Goldie JH: Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 14:29-33, 1987